Allena Pharmaceuticals to Present Virtually at Evercore ISI 3rd Annual HealthCONx Conference
Allena Pharmaceuticals (NASDAQ: ALNA) announced that its President and CEO, Louis Brenner, M.D., will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 1:25 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Allena Pharmaceuticals (NASDAQ: ALNA) announced that its President and CEO, Louis Brenner, M.D., will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, at 1:25 p.m. ET. A live audio webcast will be accessible in the 'Events and Presentations' section on the company's website, with a replay available for 30 days post-presentation.
Allena specializes in developing oral enzyme therapeutics for rare metabolic and kidney disorders, with lead candidate reloxaliase undergoing a pivotal Phase 3 trial for enteric hyperoxaluria.
Details
News Market Reaction – ALNA
The recorded move for ALNA in the trading session of this news was -0.74%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEWTON, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that Louis Brenner, M.D., Allena’s President and Chief Executive Officer, will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Thursday, December 3, 2020, at 1:25 p.m. ET.
A live audio webcast of the presentation will be available under “Events and Presentations” in the Investors section of the Company’s website at www.allenapharma.com. A replay of the webcast will be available on the Allena website for 30 days following the presentation.
About Allena Pharmaceuticals
Allena Pharmaceuticals, Inc. is a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders. Allena’s lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders. Allena is also developing ALLN-346, currently being evaluated in a Phase 1 clinical trial, for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease.
Investor Contact
Hannah Deresiewicz
Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
Media Contact
Adam Daley
Berry & Company Public Relations
212-253-8881
adaley@berrypr.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.